Please login to the form below

Not currently logged in
Email:
Password:

simeprevir

This page shows the latest simeprevir news and features for those working in and with pharma, biotech and healthcare.

Remicade safe from biosimilar competition this year, says J&J

Remicade safe from biosimilar competition this year, says J&J

On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in

Latest news

More from news
Approximately 9 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Taking a strategic approach Taking a strategic approach

    Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Medivir names new CEO Medivir names new CEO

    simeprevir). “Medivir is an attractive company in an exciting phase of its development following the successful market introduction of simeprevir,” he said.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Warehousing of HCV patients reaches new high

    Gilead’s interferon-free product sofosbuvir and Johnson &Johnson’s simeprevir appear to lead the field – receiving the highest levels of spontaneous and prompted awareness. ... However, Abbvie’s products ABT 267, ABT 333 and ABT 450 remain

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics